
|Articles|October 1, 2014
A Phase Ib Study of Pembrolizumab in Bladder Cancer
Author(s)Elizabeth Plimack, MD, MS
Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.
Advertisement
Clinical Pearls
Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.
- 33 patients with urothelial tract cancer were enrolled on this trial.
- A subset of patients experienced a decrease in tumor volume. There were 3 complete responses.
- Overall survival data seen in this study were at the top bound of historical data.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































